IL90990A - Pharmaceuticals and diagnostic preparations containing monoclonal antibodies that react with catechin and a series of cells for their production - Google Patents

Pharmaceuticals and diagnostic preparations containing monoclonal antibodies that react with catechin and a series of cells for their production

Info

Publication number
IL90990A
IL90990A IL9099089A IL9099089A IL90990A IL 90990 A IL90990 A IL 90990A IL 9099089 A IL9099089 A IL 9099089A IL 9099089 A IL9099089 A IL 9099089A IL 90990 A IL90990 A IL 90990A
Authority
IL
Israel
Prior art keywords
monoclonal antibody
cachectin
antibody
hybridoma
composition according
Prior art date
Application number
IL9099089A
Other languages
English (en)
Hebrew (he)
Other versions
IL90990A0 (en
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of IL90990A0 publication Critical patent/IL90990A0/xx
Publication of IL90990A publication Critical patent/IL90990A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL9099089A 1988-07-18 1989-07-16 Pharmaceuticals and diagnostic preparations containing monoclonal antibodies that react with catechin and a series of cells for their production IL90990A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22020688A 1988-07-18 1988-07-18

Publications (2)

Publication Number Publication Date
IL90990A0 IL90990A0 (en) 1990-02-09
IL90990A true IL90990A (en) 1994-10-21

Family

ID=22822529

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9099089A IL90990A (en) 1988-07-18 1989-07-16 Pharmaceuticals and diagnostic preparations containing monoclonal antibodies that react with catechin and a series of cells for their production

Country Status (16)

Country Link
US (1) US5658803A (fi)
EP (1) EP0351789B1 (fi)
JP (1) JP2638652B2 (fi)
AT (1) ATE173766T1 (fi)
AU (1) AU626572B2 (fi)
CA (1) CA1340018C (fi)
DE (1) DE68928857T2 (fi)
DK (1) DK69890A (fi)
ES (1) ES2124209T3 (fi)
FI (1) FI101937B (fi)
IL (1) IL90990A (fi)
NO (1) NO179615C (fi)
NZ (1) NZ229922A (fi)
PT (1) PT91201B (fi)
WO (1) WO1990000902A1 (fi)
ZA (1) ZA895372B (fi)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
EP0486526B2 (en) * 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
EP0487610B1 (en) * 1989-08-16 2000-02-09 Chiron Corporation Prohormone cleavage site blocking antibody
DE4037604A1 (de) * 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
WO1992002822A1 (en) * 1990-08-06 1992-02-20 Cetus Corporation Methods for the identification of cytokine convertase inhibitors
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
EP0565642A1 (en) * 1991-01-11 1993-10-20 Repligen Corporation Method of preventing inflammatory damage
ES2156859T5 (es) * 1991-03-18 2008-03-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP0525570A3 (en) * 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
EP0585705B1 (en) * 1992-08-28 1998-11-04 Bayer Corporation Use of monoclonal antibodies to TNF to treat bacterial meningitis
ES2108460T3 (es) * 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU3632595A (en) * 1994-09-15 1996-03-29 Verigen, Inc Porcine antibodies to tnf-alpha(alpha)
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20050045635A1 (en) * 2003-09-03 2005-03-03 Jane Dong Containers for storing articles
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CA2632519A1 (en) * 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
CN101969929B (zh) 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
CA2898354C (en) 2013-01-25 2017-11-21 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
WO1987003489A1 (en) * 1985-12-05 1987-06-18 Biogen N.V. Combinations of tumor necrosis factors and antibiotics and methods for treating tumors
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung

Also Published As

Publication number Publication date
FI101937B1 (fi) 1998-09-30
JPH03501330A (ja) 1991-03-28
IL90990A0 (en) 1990-02-09
NO901247L (no) 1990-03-16
DK69890D0 (da) 1990-03-16
AU626572B2 (en) 1992-08-06
WO1990000902A1 (en) 1990-02-08
ES2124209T3 (es) 1999-02-01
ZA895372B (en) 1990-04-25
DK69890A (da) 1990-05-15
NO179615B (no) 1996-08-05
JP2638652B2 (ja) 1997-08-06
AU3970389A (en) 1990-02-19
EP0351789A3 (en) 1990-08-01
FI901344A0 (fi) 1990-03-16
ATE173766T1 (de) 1998-12-15
DE68928857D1 (de) 1999-01-07
PT91201B (pt) 1996-12-31
NZ229922A (en) 1992-04-28
CA1340018C (en) 1998-09-01
EP0351789B1 (en) 1998-11-25
FI101937B (fi) 1998-09-30
NO179615C (no) 1996-11-13
NO901247D0 (no) 1990-03-16
PT91201A (pt) 1990-02-08
US5658803A (en) 1997-08-19
DE68928857T2 (de) 1999-08-05
EP0351789A2 (en) 1990-01-24

Similar Documents

Publication Publication Date Title
US5658803A (en) Monoclonal antibodies reactive with cachectin
US5639455A (en) Immunosuppressant
US7446175B2 (en) Antibodies to human IL-1β
US12116405B2 (en) Arthritis treatment
AU2001295490A1 (en) Antibodies to human IL-1beta
JPH0655759B2 (ja) ハイブリドインタ−フエロン及びその製造方法
MXPA02008079A (es) Uso de inhibidores de il-18.
Bonventre et al. Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo
EP0504307B1 (en) Method of treating septic shock
JPWO2020025703A5 (fi)
CN114127108A (zh) Il-17拮抗剂治疗自身免疫疾病的方法
FI102115B (fi) Diagnostiikassa käytettävä monoklonaalinen vasta-ainekoostumus ja sitä sisältävä testipakkaus
NO180637B (no) Fremgangsmåte for fremstilling av monoklonale antistoffer eller fragmenter derav
AU2017200039B2 (en) Arthritis treatment
TW202241505A (zh) 抗il-17抗體治療自體免疫性疾病和炎症的方法

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees